Drug Profile
Research programme: skin disorder therapeutics - Skinvisible Pharmaceuticals
Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Skinvisible Pharmaceuticals
- Class Aminoquinolines; Imidazoles; Naphthalenes; Small molecules
- Mechanism of Action Cell membrane modulators; Cholesterol synthesis inhibitors; Immunostimulants; Squalene monooxygenase inhibitors; Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Actinic keratosis; Basal cell cancer; Genital warts; Mycoses; Tinea
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Actinic keratosis in USA (Topical)
- 25 Apr 2023 Discontinued - Preclinical for Basal cell cancer in USA (Topical)
- 25 Apr 2023 Discontinued - Preclinical for Genital warts in USA (Topical)